Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Marco Rossi, MD, Emanuela Altomare, PhD, Cirino Botta, MD, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, MD, Paola Critelli, MD, Francesco Conforti, Maria Teresa Di Martino, PhD, Bruno Paiva, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 505.

https://doi.org/10.1182/blood-2019-122429

Published: 2019

Journal Articles

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

Blood (2019) 134 (Supplement_1): 506.

https://doi.org/10.1182/blood-2019-123974

Published: 2019

Journal Articles

A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells

Ann Marie Rossi, MS, Anna Bunin, PhD, Lawrence Iben, BS, MA, Matthew Welsch, PhD, Tanya Berbasova, PhD, Caterina Riillo, Marco Rossi, Masaki Ohuchi, PhD, Enrique Alvarez, DVM, Naoko Kawakami, Takayuki Nagasawa, PhD, Pierfrancesco Tassone, MD, David Spiegel, MD, PhD, Luca Rastelli, PhD

Blood (2019) 134 (Supplement_1): 4411.

https://doi.org/10.1182/blood-2019-131794

Published: 2019

Journal Articles

Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets

Blood (2019) 134 (Supplement_1): 4355.

https://doi.org/10.1182/blood-2019-122088

Published: 2019

Journal Articles

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Daniele Caracciolo, MD, Giada Juli, PhD, Francesca Scionti, PhD, Gaetanina Golino, PhD, Mariamena Arbitrio, MD, Emanuela Altomare, PhD, Katia Todoerti, PhD, Katia Grillone, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 3107.

https://doi.org/10.1182/blood-2019-128245

Published: 2019

Journal Articles

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia

Nicola Amodio, PhD, Giada Juli, PhD, Eugenio Morelli, MD, Maria Angelica Stamato, PhD, Maria Eugenia Gallo Cantafio, PhD, Cinzia Federico, PhD, Katia Todoerti, PhD, Emanuela Altomare, Katia Grillone, PhD, Marco Rossi, MD, Michele Cea, MD, Antonino Neri, MD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2018) 132 (Supplement 1): 1585.

https://doi.org/10.1182/blood-2018-99-110928

Published: 2018

Journal Articles

Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation

Francesco Iuliano, MD, Eleonora Iuliano, MD, Marco Rossi, MD

Blood (2018) 132 (Supplement 1): 2449.

https://doi.org/10.1182/blood-2018-99-118518

Published: 2018

Journal Articles

Assisted Administration of Subcutaneous Rituximab to the Patient's Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety

Francesco Iuliano, MD, Eleonora Iuliano, MD, Marco Rossi, MD

Blood (2018) 132 (Supplement 1): 5869.

https://doi.org/10.1182/blood-2018-99-118756

Published: 2018

Journal Articles

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Cirino Botta, MD, Giuseppe Gaipa, PhD, Maria Eugenia Gallo Cantafio, PhD, Chiara Buracchi, PhD, Maria Anna Siciliano, MD, Caterina Riillo, MD, Katia Grillone, PhD, Alessandro Gulino, Maria Cucè, Nicoletta Staropoli, Andrea Ghelli Luserna Di Rora, Franca Maria Tuccillo, Maria Teresa Di Martino, Claudio Tripodo, MD, Marco Rossi, MD, Giovanni Martinelli, Andrea Biondi, MD, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2018) 132 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2018-99-118572

Published: 2018

Journal Articles

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Blood (2018) 132 (10): 1050–1063.

https://doi.org/10.1182/blood-2018-03-836601

Published: 2018

Includes: Supplemental data

Journal Articles

Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease

Marco Rossi, Emanuela Altomare, Nicola Amodio, PhD, Maria Teresa Di Martino, Marco Gaspari, Domenico Taverna, Domenica Scumaci, Francesco Conforti, Daniele Caracciolo, Cirino Botta, Cinzia Federico, Annamaria Gullà, Eugenio Morelli, Francesca Scionti, Mariamena Arbitrio, MD, Paola Critelli, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2017) 130 (Supplement 1): 4380.

https://doi.org/10.1182/blood.V130.Suppl_1.4380.4380

Published: 2017

Journal Articles

LNA -Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade

Nicola Amodio, PhD, Maria Angelica Stamato, PhD, Giada Juli, PhD, Eugenio Morelli, Martina Manzoni, Elisa Taiana, Marco Rossi, Mariamena Arbitrio, MD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2017) 130 (Supplement 1): 1762.

https://doi.org/10.1182/blood.V130.Suppl_1.1762.1762

Published: 2017

Journal Articles

Multiple Myeloma in Patients with HCV-Related Disease:a Case Report

Iolanda D. Vincelli, Patrizia Cufari, Francesco Di Raimondo, MD, Martino Massimo, Massimo Gentile, MD, Fortunato Morabito, Stefania Ciolli, Marco Rossi, MD, Francesca Ronco

Blood (2016) 128 (22): 5700.

https://doi.org/10.1182/blood.V128.22.5700.5700

Published: 2016

Journal Articles

Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines

Lavinia Biamonte, PhD, Cinzia Federico, PhD, Eugenio Morelli, MD, Emanuela Leone, PhD, Maria Eugenia Gallo Cantafio, PhD, Maria Teresa Di Martino, Nicola Amodio, PhD, Marco Rossi, MD, Antonino Neri, Pr, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2015) 126 (23): 3019.

https://doi.org/10.1182/blood.V126.23.3019.3019

Published: 2015

Journal Articles

Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability

Teresa Calimeri, MD PhD, Daniele Caracciolo, MD, Nicola Amodio, PhD, Mehmet Kemal Samur, PhD, Marzia Leotta, MD, Mariateresa Fulciniti, PhD, Marco Rossi, MD, Stephane Minvielle, Herve Avet-Loiseau, Pierosandro Tagliaferri, MD, Masood Shammas, PhD, Kenneth C. Anderson, Pierfrancesco Tassone, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3417.

https://doi.org/10.1182/blood.V124.21.3417.3417

Published: 2014

Journal Articles

MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma

Nicola Amodio, PhD, Marzia Leotta, MD, Anna Maria Gullà, MD, Lavinia Raimondi, PhD, Eugenio Morelli, MD, Maria Angelica Stamato, Teresa Calimeri, MD PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Emanuela Leone, PhD, Antonino Neri, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2014) 124 (21): 2060.

https://doi.org/10.1182/blood.V124.21.2060.2060

Published: 2014

Journal Articles

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Cirino Botta, MD, Marco Rossi, MD, Maria Rita Pitari, PhD, Annamaria Gullà, MD, Teresa Del Giudice, MD, Eugenio Morelli, MD, Eleonora Iuliano, MD, Emanuela Altomare, PhD, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Pierpaolo Correale, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 4489.

https://doi.org/10.1182/blood.V122.21.4489.4489

Published: 2013

Journal Articles

Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells

Nicola Amodio, PhD, Marzia Leotta, MD, Lavinia Biamonte, PhD, Teresa Calimeri, MD, Eugenio Morelli, MD, Umberto Foresta, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Emanuela Leone, PhD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 4451.

https://doi.org/10.1182/blood.V122.21.4451.4451

Published: 2013

NARROW

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells

Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia

Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation

Assisted Administration of Subcutaneous Rituximab to the Patient's Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease

LNA -Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade

Multiple Myeloma in Patients with HCV-Related Disease:a Case Report

Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines

Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability

MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only